Introduction
B-cell CLL is the most common adult leukemia in the western hemisphere. It manifests with a variable clinical course that is characterized by progressive disease and short survival in approximately half of the cases and a relatively stable disease and normal lifespan in the remaining patients. 1 In recent years, several molecular correlates of progressive disease and unfavorable clinical outcome have been identified, which are increasingly being used as prognostic factors. These include the absence of mutations in the immunoglobulin variable heavy chain (V H ) genes, expression of the z-chain associated protein 70 kDa (ZAP-70), expression of the CD38 antigen and the presence of certain cytogenetic abnormalities, such as deletions at 17p13 and 11q22-23. [2] [3] [4] [5] [6] [7] [8] [9] [10] Chronic lymphocytic leukemia (CLL) is defined as a malignancy of mature B-lymphocytes that have an extended survival but low proliferative potential. In the peripheral blood, the vast majority of CLL B-cells are arrested at the G 0 /early G 1 phase of the cell cycle. However, a proliferating compartment is present in specialized structures called pseudofollicles that are located in lymph nodes and bone marrow of CLL patients. 11 Recent in vivo measurements of CLL B-cell kinetics have indicated that this proliferating compartment is larger than previously anticipated, considering that the birth rate of CLL B-cells in many cases was found to exceed the birth rate of normal B-lymphocytes. 12 More interestingly, high leukemic cell birth rate was found to correlate with disease progression, indicating that the difference in clinical course may, at least in part, be determined by the proliferative capacity of the CLL B-cells.
The proliferative potential of CLL B-cells belonging to different prognostic subgroups has not been examined in detail. In vitro, CLL B-cells are usually hyporesponsive to proliferative signals that activate normal B-lymphocytes. 13, 14 However, CLL B-cells can be induced to proliferate by certain stimuli, such as triggering of the CD40 receptor or stimulation with CpGoligodeoxynucleotides (CpG ODN). 13, [15] [16] [17] [18] The latter mimic CpG motifs present in unmethylated bacterial DNA, which are recognized by Toll-like receptor 9 (TLR9). This interaction activates several downstream signaling pathways, including NF-kB, phosphatidylinositol 3-kinase (PI3K)/Akt and the mitogen activated protein kinases JNK, ERK1/2 and p38MAPK. [19] [20] [21] In normal B-cells activation of these pathways results in upregulation of costimulatory molecules, cell cycle entry and proliferation. 22 The response of CLL B-cells to CpG ODN stimulation is considerably more heterogeneous. In several smaller series proliferation was induced in approximately half of the cases, and this effect was further augmented by addition of interleukin-2 (IL-2). 17, 18 However, induction of apoptosis was also observed in a fraction of cases, indicating that CpG ODN stimulation has a pleiotropic effect on leukemic cell growth and survival. 18, 23 In this study we investigated what are the signaling events that underlie the different responsiveness of CLL B-cells to CpG ODN induced proliferation and whether the different responses are associated with distinct prognostic and clinical features of CLL. We show that leukemic B-cells from patients with progressive disease have a higher capacity for cell cycle progression, which is related to stronger activation of the Akt signaling pathway.
Materials and methods

Patients and cell samples
Blood samples were collected from 58 patients that satisfied standard morphologic and immunophenotypic criteria for B-cell CLL. 24 Informed consent was obtained from all patients according to the Declaration of Helsinki and approval for the study was obtained from the institutional human research committee at the Catholic University Medical School in Rome. Forty patients (69%) were male, and median age was 64 years (range . Twenty-two patients (38%) had received treatment for symptomatic or progressive disease, according to the National Cancer Institute Working Group Criteria. None of the patients that were investigated had received chemotherapy or steroids for a period of at least 3 months before the sampling. Progressive and stable disease were defined according to standard guidelines. 24 Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll gradient centrifugation (Amersham Biosciences, Uppsala, Sweden). The samples that were used had at least 80% CD5
þ CD19 þ cells, as assessed by flow-cytometry. In some experiments CLL B-cells were purified by negative selection using anti-CD3, anti-CD14 and anti-CD16 mouse monoclonal antibodies (kindly provided by F Malavasi) and Dynabeads coated with a pan anti-mouse IgG antibody (Dynal Biotech, Oslo, Norway). The purity of the selected CLL B-cells was more than 98%.
Cell culture and proliferation assays
Freshly isolated CLL B-cells were resuspended at a density of 0.8-1.2 Â 10 7 cells/ml in Rosewell's Park Memorial Institute media-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate (Invitrogen, Carlsbad, CA, USA) and cultured at 371C in a humified atmosphere containing 5% CO 2 . Stimulations were performed with 7.5 mg/ml complete phosphorothioate CpG oligonucleotide 2006 (5 0 -TCGTCGTTTTGTCGTTTTGTCGTT-3 0 ) or the control non-CpG oligonucleotide 1982 (5 0 -TCCAGGACTTCTCTCAGG TT-3 0 ) (Microsynth, Balgach, Switzerland). In some experiments CLL B-cells were incubated for 2 h with the following pharmacological inhibitors before the stimulations: 10 mM LY294002, 10 mM U0126 (Cell Signaling, Beverly, MA, USA), 50 nM rapamycin, 10 mM SB203580 (Sigma, Saint Louis, MO, USA), 4 mM BAY-11 and 10 mM SP600125 (Calbiochem, La Jolla, CA, USA).
For proliferation assays, CLL B-cells were cultured at 2 Â 10 5 / well in 96-well flat-bottom plates for 48 h followed by the addition of [ 3 H]thymidine (1 mCi/well) for the next 16 h. The cells were harvested on filters and the incorporation of [ 3 H]thymidine in cellular DNA was measured on a b-counter (Beckmann, Munich, Germany).
Immunoblot analysis
Cell pellets were lysed in ice-cold 1% Nonidet P-40 (NP-40) lysis buffer containing 1:40 dilution of protease inhibitor cocktail for mammalian cells and 1:70 dilution of phosphatase inhibitor cocktail 2 (both from Sigma-Aldrich). The protein samples were separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred on Immobilon-P polyvinilidene difluoride membranes. The amount of protein that was loaded ranged from 40 to 80 mg/ lane, depending on the antibodies that were subsequently used. Membranes were blotted at 41C with the following antibodies:
, phospho-p38 MAPK Thr180/Tyr182 , Akt, IkB-a, JNK, ERK, Toll-like Receptor 9, rabbit IgG-HRP, mouse IgG HRP-linked (all from Cell Signaling), cyclin D2, cyclin D3, cyclin E, cyclin A, p27KIP1, p21CIP1, (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), HA-peroxidase (Roche Diagnostics, Monza, Italy), b-actin and tubulin (Sigma-Aldrich). Immunodetection was performed with the ECL Plus enhancedchemiluminescence detection system (Amersham Biosciences, Buckinghamshire, UK) and BioMax MR films (Eastman Kodak, Rochester, NY, USA). Protein bands were quantified by laser densitometry and analyzed by ImageQuant software (Amersham Biosciences).
Analysis of cell viability and apoptosis
Induction of apoptosis was analyzed by double staining with fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidium iodide (PI) using the ApoAlert Annexin V kit (BD Biosciences, Palo Alto, CA, USA), according to the manufacturer's instructions. Briefly, 1 Â 10 6 cells were washed once with phosphate-buffered saline (PBS) and resuspended in 200 ml binding buffer with 0.5 mg/ml Annexin V-FITC and 2 mg/ml PI. After incubation for 10 min at room temperature in a light protected area, the samples were analyzed on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). Data analysis was performed with CellQuest software (Becton Dickinson). Cell viability was measured as the percentage of Annexin V-and PI-double negative cells.
DNA constructs and transfections
The myristoylated AKT (myr-Akt) construct was created by excising from the pCMV-myr-AKT plasmid (provided by D Pim) the DNA fragment encoding full-length AKT1 that carries at the N-terminal part the myristoylated signal peptide of the Lck kinase. This fragment was subcloned into the HindIII-BamHI sites present in the polylinker of the mammalian expression vector pcDNA3. The constitutively activated MEK2 construct (pUSEamp-MEK2 S222D/S226D ) was purchased from Upstate Technology (Lake Placid, NY, USA). The plasmid DNAs were purified with the Plasmid Maxi Kit (Qiagen, Hilden-Germany).
The pcDNA3, pcDNA3-myr AKT and pUSEamp-MEK2 S222D/ S226D vectors were introduced into purified CLL B-cells with the Nucleofector system (Amaxa Biosystems GmbH, Cologne, Germany). Typically, 1.2 Â 10 7 cells were resuspended in 100 ml of Cell Line Nucleofector Solution V and mixed with 3 mg of plasmid DNA. To evaluate transfection efficiency, the same number of cells were transfected with the GFP-expressing construct pmaxGFP (Amaxa Biosystems). Nucleofections were performed using the Amaxa Nucleofector II device and the U-13 program. Cell viability and transfection efficiency were evaluated on 5 Â 10 5 GFP-nucleofected cells after 5 h by PI staining and flow-cytometry analysis. The transfection efficiency ranged from 40 to 60%, based on the number of PI-negative/GFPpositive cells. Stimulation with CpG ODN was started 5-6 h postnucleofection. Forty-eight hours after nucleofection the cells were collected and processed for immunoblotting assays.
Ig V H gene sequence analysis
Polymerase chain reaction (PCR) amplification, cloning, and sequencing of V H region genes were performed using standard methodology. Briefly, RNA was reverse transcribed using random hexamers and then PCR amplified with a degenerate V H FWR1 primer in combination with Cm, Cg and Ca reverse primers. PCR products were purified with the QIAquick PCR purification kit (Qiagen, Valencia, CA, USA) and either sequenced directly or cloned with the PCR cloning plus kit (Qiagen). Sequencing was performed with the BigDye Terminator v3.1 Cycle Sequencing kit and ABI 3100 genetic analyzer (Applied Biosystems, Forster City, CA, USA). Candidate germline genes were assigned by searching the VBASE directory. Sequences with less than 2% differences from germline V H sequences were considered unmutated.
Real-time PCR analysis
RNA quality and concentration were analyzed with Agilent 2100 Bioanalyzer using the RNA 6000 Pico kit (Agilent Technologies, Inc., Santa Clara, CA, USA). First strand cDNAs were generated from 500 ng of total RNA by using the T-primed first strand Kit Ready-To-Go (Amersham Biosciences). Real-time quantitative PCR was performed on the Sequence Detection System ABI Prism 7700 (Applied Biosystems) using TaqMan gene expression assays for TLR9 and b-actin (housekeeping gene), according to the manufacturer's recommendations (Applied Biosystems). Samples were run in triplicate and relative quantification was performed with the comparative C t method. with progressive disease and in only seven of 36 cases (19.4%) with stable disease (P ¼ 0.002, Mann-Whitney rank sum test). A significant association was also noted with respect to V H gene mutation status, with proliferation occurring in 15 of the 24 V H unmutated (62.5%) and in only six of the 34 V H mutated CLL B-cell samples (17.6%, P ¼ 0.001). Positive associations were also observed with expression of ZAP-70 (P ¼ 0.042) and the presence of adverse cytogenetic abnormalities (11q22 deletion, 17p13 deletion and/or trisomy 12; P ¼ 0.017), but data on these prognostic factors were not available for all patients (clinical and laboratory features of the cases included in the study are presented in Supplementary Table 1) .
Statistical analysis
The proliferative response to CpG ODN stimulation appeared to be a constant feature of the CLL clone, considering that similar levels of [ 3 H]thymidine incorporation were observed in repetitive samples that were collected at various timepoints in 19 patients (Supplementary Figure 1) . Moreover, none of the cases converted from proliferating to nonproliferating or vice versa. However, it should be noted that none of these patients had experienced a change in clinical course at the time the second or third sample was collected, thus preventing any conclusions whether the proliferative capacity changes with disease progression.
In 15 different cases we also compared the proliferative response of purified and unpurified CLL B-cells. The responses observed with purified CLL B-cells always paralleled the responses of unpurified CLL B-cells, but the c.p.m. values were lower (Supplementary Figure 2A) . This indicates that other cell types present in the sample enhance the proliferation of the CLL B-cells, possibly by secreting growth-promoting cytokines such as IL-2. 17 Finally, in 10 cases we investigated the effect of the phosphorothioate oligonucleotide ODN 1982, which does not contain a CpG motif. 25 The non-CpG ODN also induced proliferation, although the response was weaker in comparison following stimulation with non-CpG phosphorothioate oligonucleotides has already been reported by other groups and presumably reflects the activity of other immunostimulatory sequences, such as thymidine-rich motifs. 16, 17, [26] [27] [28] Activation of B-cells following internalization of CpG ODN requires signaling through TLR9, although recent studies indicate that other nucleic acid sensors may also be involved. 29, 30 As the levels of TLR9 vary during B-cell differentiation and can be modulated by antigen encounter, we investigated whether the different proliferative responses were associated with differences in the expression of this receptor. We first examined the relative levels of TLR9 mRNA in 17 purified CLL B-cell samples by real-time reverse transcription (RT)-PCR. As shown in Figure 2a , the levels of TLR9 mRNA varied widely, ranging from approximately 10 fold higher to 10 fold lower levels with respect to the B-cell lymphoma cell line BJAB, which was used as a calibrator. However, comparison of TLR9 mRNA levels with [ 3 H]thymidine incorporation did not reveal any correlation, indicating that differences in TLR9 expression do not account for the distinct proliferative responses. This was further supported by analyzing TLR9 protein levels in purified CLL B-cells from 13 additional cases. As shown in Figure 2b , low levels of TLR9 protein (less than 10% of the levels in the BJAB cell line) were detected by immunoblotting in three of the seven proliferating cases (samples G141, G41 and G147), whereas considerable amounts were expressed in two of the six nonproliferating samples (G84 and G43). The levels of TLR9 protein appeared relatively constant, since identical amounts were detected in two samples from the same patient collected during a 4-month interval (samples G4a and G4b).
The high levels of TLR9 mRNA and protein detected in some of the nonproliferating cases indicated that the nonresponsiveness to CpG ODN stimulation is not due to inadequate TLR9 expression. Moreover, we observed that most nonproliferating CLL B-cell samples undergo apoptosis after 48 h in culture with CpG ODN, indicating that these CLL B-cells also respond to CpG ODN stimulation, but with a different outcome (Figure 2c ). Analysis of CLL B-cell survival after 48 h of CpG ODN stimulation in an extended series of 27 cases, which also included samples that had not been investigated for 
Ratio: Prolif. [ 3 H]thymidine incorporation, showed induction of apoptosis in the majority of cases with stable disease and mutated V H genes, whereas an increase in the percentage of viable cells was observed in the majority of cases with progressive disease and unmutated V H genes (P ¼ 0.007 and 0.004, respectively, t-test).
CLL B-cells that proliferate in response to CpG ODN stimulation show enhanced activation of Akt, ERK, JNK, p38 MAPK and NF-kB We next investigated whether the different proliferative responses resulted from differences in the activation of signaling pathways that are known to be activated by CpG ODN in normal B-cells. As shown in the examples in Figure 3a , activation of the Akt, ERK, JNK and p38 MAPK kinases and degradation of the NF-kB inhibitor IkB was induced in CLL B-cells from both subgroups, including cases that did not incorporate [ 3 H]thymidine. These experiments were performed using seven proliferating and six nonproliferating CLL B-cell samples, with similar results. However, a major difference was observed between these subgroups in terms of the intensity and the duration of the signaling response. In particular, phosphorylation of Akt, ERK, JNK and p38 MAPK appeared stronger and more durable in CLL B-cells that proliferated in response to CpG ODN stimulation. The latter was especially evident for ERK, which was only transiently phosphorylated in nonproliferating CLL B-cells, whereas the signal lasted more than 24 h in CLL B-cells that were induced to proliferate by CpG ODN.
To quantify the difference in the activation of these signaling molecules and confirm that they become more strongly activated in proliferating CLL B-cells, we performed a second set of experiments in which pairs of one proliferating and one Pairs of one proliferating and one nonproliferating sample were loaded on the same gel and analyzed by immunoblotting. Densitometric measurements of total-and phosphoprotein levels were performed for each pair, and the normalized value of the proliferating sample was divided by the normalized value of the nonproliferating sample to determine the difference in phospho-protein levels. The mean values and s.e. of four pairs analyzed in this manner are shown in the graph. To compare changes in IkB levels, the percentage of degraded IkB after 1 h stimulation was calculated with the following formula: 100 -(IkB CpG /actin CpG )/(IkB medium /actin medium ) Â 100.
Akt signaling and CLL cell cycle regulation PG Longo et al nonproliferating CLL B-cell sample were stimulated with CpG ODN and loaded on the same gel. Following immunoblotting, total-and phosphoprotein levels were determined by densitometry and the normalized phospho-specific signal of the proliferating sample was compared to the phospho-specific signal of the nonproliferating sample. Mean values of four such experiments were determined, which showed a 5 to 6-fold stronger induction of Akt and ERK phosphorylation and a similar 3 to 4-fold greater increase in JNK and p38 MAPK phosphorylation in the proliferating cases (Figure 3b, top panel) . A similar difference was noted in terms of IkB degradation, which showed almost complete disappearance of the protein following 1 h of CpG ODN stimulation in the proliferating cases, whereas considerable levels of IkB were still present in some of the nonproliferating samples (Figure 3b , bottom panel, and data not shown). Thus, although only semiquantitative, these experiments further support the conclusion that the Akt, ERK, JNK, p38 MAPK and NF-kB pathways become more strongly activated in CLL B-cells that proliferate following CpG ODN stimulation.
Reduced or absent induction of cyclin E and cyclin A in CLL B-cells that do not proliferate in response to CpG ODN stimulation
The signaling pathways activated by CpG ODN function in part to initiate cell cycle entry by inducing changes in the levels of key cell cycle regulatory proteins, such as the positive regulators cyclin D2, cyclin D3, cyclin E and cyclin A and the cyclindependent kinase (cdk) inhibitors p27KIP1 and p21CIP1. 31, 32 Stimulation with CpG ODN resulted in strong induction of cyclin D3 and downregulation of p27KIP1 in 4/4 proliferating and 5/5 nonproliferating CLL B-cell samples, indicating that all CLL B-cells enter the G 1 phase of the cell cycle ( Figure 4 ). Cyclin D2 and p21CIP were only weakly detected and their levels did not change substantially following CpG ODN stimulation, which may reflect a nonessential role for these proteins in cell cycle regulation of CLL B-cells in this setting. Analysis of proteins that regulate later phases of the cell cycle revealed major differences between the proliferating and nonproliferating samples. In particular, induction of cyclin E, which is involved in late G 1 phase progression, was reduced or absent in the nonproliferating cases. Moreover, CpG ODN stimulation in these samples failed to induce cyclin A, which is expressed in the S phase of the cell cycle. In contrast, high levels of cyclin A were detected after 48 h of stimulation in CLL B-cells that were responsive to CpG ODN induced proliferation.
Activation of Akt, ERK and JNK is required for cell cycle progression and proliferation of CLL B-cells
The observed differences in the amplitude and kinetics of Akt, ERK, JNK, p38 MAPK and NF-kB activation indicated that one or more of these signaling pathways is responsible for the diverse Proliferation was also substantially inhibited by U0126 and SP600125, which prevent activation of the ERK and JNK kinases, respectively. In contrast, the p38 MAPK inhibitor SB203580 and the NF-kB inhibitor BAY-11 had only a minor effect.
We next investigated whether inhibition of these signaling pathways is associated with specific changes in the levels of the cell cycle regulatory proteins whose expression was altered by CpG ODN stimulation. As shown in Figure 5b , inhibition of the PI3K/Akt/mTOR pathway by LY294002 and rapamycin almost completely prevented the CpG ODN-induced upregulation of cyclin D3, cyclin E and cyclin A, as well as the downregulation of p27KIP1. A similar effect was noted with the JNK inhibitor SP600125, although it appeared slightly less active. The ERK inhibitor U0126 had almost no effect on cyclin D3 expression and only weakly inhibited cyclin E induction and p27KIP1 downregulation, but substantially inhibited expression of cyclin A. In accordance with the lymphocyte proliferation experiments, the p38 MAPK inhibitor SB203580 and the NF-kB inhibitor BAY-11 did not downmodulate any of the changes induced by CpG ODN-stimulation. Taken together, these data indicate that signaling through Akt, JNK and ERK is required for CpG ODN-induced cell cycle progression and proliferation of CLL B-cells.
Enforced activation of Akt induces cell cycle progression in CLL B-cells that are nonresponsive to CpG ODN-induced proliferation
Previous studies have shown that the amplitude and duration of Akt and ERK signaling are critical factors in determining cell cycle progression in various cell types. [33] [34] [35] [36] Although a role for JNK in B-cell proliferation has also been established, it is still not known whether quantitative differences in JNK activation can influence cell cycle progression. [37] [38] [39] We therefore decided to further investigate the possibility that the stronger proliferative response of progressive/V H unmutated CLL B-cells is due to increased signaling through the Akt or ERK pathway. To enforce activation of these kinases, we transfected primary CLL B-cells that were nonresponsive to CpG ODN-induced proliferation with constitutively active MEK2 and myristoylated Akt constructs. The MEK2 kinase activates ERK, whereas the myristoylation sequence promotes membrane translocation and activation of Akt. CLL B-cells to proliferative stimuli is determined mainly by Aktdependent pathways.
Discussion
In recent years a number of genetic and biological differences have been identified between CLL patients with progressive and stable disease. Many of these differences, such as Ig V H gene mutation status and ZAP-70 expression, have proved extremely valuable as prognostic factors, but thus far have not provided a comprehensive explanation for the clinical and biological heterogeneity of CLL. The absence of somatic mutations in the Ig V H genes and expression of ZAP-70 have been associated with enhanced B-cell receptor signaling, but it is still unclear whether this difference is sufficient to account for the growth advantage of the leukemic B-cells in patients with progressive disease. 40, 41 In this study we used an in vitro model of CLL B-cell proliferation to investigate whether disease activity correlated with quantitative or qualitative differences in cell cycle regulation. We show that CLL B-cells from most patients with progressive disease respond to immunostimulatory DNA oligonucleotides, such as CpG ODN, by cell cycle progression, proliferation and enhanced survival. In contrast, CpG ODN stimulation induced cell cycle arrest and leukemic cell apoptosis in the majority of cases with stable disease. These different responses were also noted when the CLL cases were grouped according to V H gene mutation status, with proliferation and prolonged survival preferentially occurring in the V H unmutated and induction of apoptosis in the V H mutated subset. Moreover, analysis of serial samples showed that the proliferative response to CpG ODN stimulation is a constant feature of the malignant clone, at least in patients that had not experienced a change in disease activity. Further studies will be required to determine whether the proliferative response changes with disease progression.
Analysis of the expression of cell cycle regulatory proteins following CpG ODN stimulation showed that the distinct proliferative responses are associated with a different capacity of CLL B-cells to traverse through the G 1 /S checkpoint of the cell cycle. In particular, these experiments showed that leukemic B-cells from both CLL subsets enter into the early G 1 phase of the cell cycle, as evidenced by the upregulation of cyclin D3 and downregulation of p27KIP1 in all investigated samples. However, induction of cyclin E, which is involved in late G 1 and S phase progression, was reduced or absent in CLL B-cells that were nonresponsive to CpG ODN-induced proliferation. Moreover, cyclin A, which is expressed in the S phase of the cell cycle, was strongly induced in CLL B-cells that proliferated in response to CpG ODN stimulation, but was not detected in the nonproliferating samples. These data indicate that CLL B-cells from both prognostic subsets become sufficiently activated to enter into the cell cycle, but they differ in their capacity for subsequent cell cycle progression.
The expression of cell cycle regulatory proteins is determined by a number of signaling pathways that are activated by various growth factors and other mitogenic stimuli. 31, 32 In various cell types critical proliferative signals are transmitted through Akt, ERK, JNK, p38 MAPK and the NF-kB pathway, which have all been shown to be activated by CpG ODN stimulation. 42, [19] [20] [21] [22] We observed that activation of these signaling molecules is stronger and/or prolonged in the proliferating CLL samples, indicating that differences in the amplitude and/or kinetics of the CpG ODN-induced signal may be responsible for the observed differences in the proliferative response. To determine which of these signaling pathways are required for CLL B-cell proliferation, we employed specific pharmacological inhibitors and evaluated their effect on CpG ODN-induced proliferation. Inhibition of the PI3K/Akt/mTOR, ERK and JNK pathways resulted in complete inhibition of the proliferative response, indicating that activation of these pathways is essential for leukemic cell proliferation in this setting. Accordingly, inhibition of the PI3K/Akt/mTOR and JNK pathways abrogated the CpG ODN-induced changes in expression of cyclin D3, p27KIP1, cyclin E and cyclin A. The effect of the ERK inhibitor was confined mainly to inhibition of cyclin A induction, indicating that this pathway plays a more prominent role in regulating later stages of the cell cycle in CLL B-cells. In contrast, inhibition of the p38 MAPK and NF-kB pathways did not substantially affect CpG ODN-induced proliferation nor the expression of the cell cycle regulatory proteins. Although these pathways have also been shown to influence cell cycle progression, in CLL they may be more involved in regulating leukemic cell survival and cytokine production. 37, [43] [44] [45] [46] [47] [48] The experiments with the pharmacological inhibitors indicated that the strength of Akt, ERK and/or JNK activation determines the different proliferative response of CLL B-cells belonging to distinct clinical and prognostic subsets. The Akt and ERK kinases appeared as more likely candidates for such an explanation, because differences in the magnitude and duration of Akt and ERK signaling have already been shown to exert substantial effects on the cellular response in a number of different cell types. For example, sustained activation of ERK lasting at least several hours is required for proliferation of fibroblasts, whereas transient activation does not induce cell cycle entry. 33, 34 Similarly, sustained activation of the PI3K/Akt pathway is required to drive cell cycle progression in activated T-and B-cells. 35, 36 Therefore, to further investigate whether insufficient activation of these kinases is responsible for the lower proliferative capacity of the prognostically favorable CLL B-cell subset, we introduced cDNA constructs encoding for constitutively active MEK2 and constitutively active Akt in primary CLL B-cells that were nonresponsive to CpG ODN-induced proliferation. Although both constructs were efficiently transfected, induction of cyclin A following CpG ODN stimulation was observed only in CLL B-cells transfected with constitutively active Akt, whereas cyclin A was not induced in cells with enforced activation of ERK. This result was somewhat surprising, considering that the main consequence of pharmacological inhibition of ERK was to prevent cyclin A induction. However, Akt has also been shown to regulate the G 1 -S phase transition, for example by stabilizing and increasing the activity of the cyclin E/Cdk2 complex, which is required for cell cycle progression. 49 The capacity of Akt to overcome by itself the hyporesponsiveness of CLL B-cells to CpG ODN stimulation indicates that ERK and JNK, which were also required for CLL B-cell proliferation, become sufficiently activated even in nonproliferating CLL B-cells. Moreover, these experiments indicate that the different capacity of CLL B-cells to traverse the cell cycle and proliferate in response to CpG ODN is related primarily to the strength of Akt activation. An important role for Akt in CLL pathogenesis is also supported by the development of a CLL-like disorder in mice transgenic for the TCL-1 oncoprotein, which augments Akt signal transduction. 50 Progression of the lymphoproliferative disorder in these mice can significantly be delayed by rapamycin, which was shown to completely inhibit CpG ODN-induced CLL B-cell proliferation both in our study and in an earlier report. 51, 52 Akt has also been shown to promote the survival of CLL B-cells and becomes activated by a number of prosurvival stimuli, such as IL-4, phorbol ester, human albumin and immobilized anti-IgM. 46, [53] [54] [55] It will therefore be interesting to investigate whether also these stimuli induce quantitatively different signals in the two CLL subsets, which could lead to greater survival advantage of the leukemic clone in the prognostically unfavorable group.
The reason for the stronger CpG ODN-induced signaling in CLL B-cells from patients with progressive disease and unmutated V H genes remains unclear at present. One possibility that was excluded in this study was the level of expression of the CPG ODN receptor TLR9. Studies with normal human B-lymphocytes have shown that TLR9 levels vary during development, with low levels in naive and high levels in memory and antigen-stimulated B-cells. 56 Considerable variations in the levels of TLR9 mRNA and protein were also observed in the CLL B-cell samples investigated in our series, but these differences did not correlate with the proliferative response. Interestingly, a study investigating the effects of CpG ODN stimulation on CLL B-cell survival also reported a lack of correlation between expression of TLR9 and induction of apoptosis. 23 Together, these data indicate that the different responsiveness of CLL B-cells to CpG ODN stimulation is determined by signaling molecules that are distal to TLR-9. Alternatively, some of the effects of CpG ODN on CLL B-cell proliferation and survival could be mediated by TLR-9 independent pathways. 29 CpG ODN have recently received considerable attention as potential therapeutic agents in CLL, especially in light of findings that leukemic cell apoptosis induced by the BCL-2 antisense oligonucleotide G3139 may not depend on antisensemediated reduction in BCL-2 expression, but rather on its immunostimulatory properties. 57 The same authors also noted that apoptosis was induced primarily in CLL B-cells with favorable cytogenetic abnormalities, such as 13q14 deletion as a single aberration, whereas the effect was heterogeneous in samples with poor prognosis cytogenetic abnormalities, such as 17p13, 11q22-23 and trisomy 12. 23 Our data further expand these observations, showing that CpG ODN induce apoptosis primarily in CLL B-cells from patients with stable disease and mutated V H genes. In contrast, leukemic cells from patients with progressive disease and unmutated V H genes showed increased survival, at least during the first 48 h of CpG ODN stimulation. These observations indicate that CpG ODN may not be effective in patients that are most likely to require treatment, unless pathways that regulate prosurvival signaling are not blocked simultaneously. Characterization of these pathways may therefore allow the design of combination therapy with specific pharmacological inhibitors to improve the efficacy of antisense and/or CpG oligonucleotide treatment of CLL.
